NFE2L2 and non-small cell lung carcinoma: Among 154 responders and 265 non‐responders to anti‐PD1 therapy in NSCLC, Nrf2 expression was significantly higher in the non‐responders (Figure 2A, right), suggesting a potential role of Nrf2 in mediating resistance to immunotherapy.